Dupilumab for atopic dermatitis treatment: A single-center retrospective study
TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, cilt.56, sa.1, ss.12-16, 2022 (ESCI)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 56 Sayı: 1
- Basım Tarihi: 2022
- Doi Numarası: 10.4274/turkderm.galenos.2021.36604
- Dergi Adı: TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.12-16
- Anahtar Kelimeler: Atopic dermatitis, dupilumab, treatment, 2-PHASE 3 TRIALS, PLACEBO, MANAGEMENT, ADULTS
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Akdeniz Üniversitesi Adresli: Evet
Özet
Background and Design: Atopic dermatitis (AD) is a common chronic, recurrent, and itchy inflammatory skin disease. Various therapeutic agents are available, but severe side effects may limit their usage. Recently, dupilumab, a human monoclonal antibody that targets the interleukin-4 (IL-4) receptor alpha subunit of heterodimeric IL-4 and IL-13 receptors, is approved and might be used in patients with resistant AD, with the permission of the Ministry of Health.